Incidence of genitourinary conditions in women with a diagnosis of vulvar/vaginal atrophy

Current Medical Research and Opinion

Volumn 30, Issue 1, 2014, Pages 143-148

  Constantine, Ginger D ^a   Bruyniks, Nico ^b   Princic, Nicole ^c   Huse, Daniel ^c   Palmer, Liisa ^c   Lenhart, Greg ^c   Blumentals, William A ^d   Nappi, Rossella E ^e  

^a EndoRheum Consultants LLC   (United States)

^b BrInPhar Ltd   (United Kingdom)

^c IBM WATSON HEALTH   (United States)

^d SHIONOGI AND CO LTD   (Japan)

^e UNIVERSITY OF PAVIA   (Italy)

Author keywords

Clinical classification software; Genitourinary conditions; ICD 9 CM diagnosis; Incidence; Vulvar vaginal atrophy

Indexed keywords

ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ADULT; AGED; AMBULATORY CARE; ANGINA PECTORIS; ANXIETY; ARTICLE; ATROPHIC VAGINITIS; CHARLSON COMORBIDITY INDEX; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; FEMALE; FEMALE GENITAL PAIN; HOSPITALIZATION; HUMAN; INCIDENCE; INSOMNIA; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; MIGRAINE; OSTEOPOROSIS; RISK FACTOR; SUPPLEMENTATION; URINARY TRACT INFECTION; VAGINA ATROPHY;

ADULT; AGED; ATROPHY; ESTROGENS; FEMALE; HUMANS; INCIDENCE; MENOPAUSE; MIDDLE AGED; POSTMENOPAUSE; UNITED STATES; URINARY TRACT; UROLOGIC DISEASES; VAGINA; VAGINAL DISEASES; VULVA; VULVAR DISEASES;

EID: 84890452006     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2013.850068     Document Type: Article

References (18)

1. US Food and Drug Administration. Guidance for industry. Estrogen and estrogen/ progestin drug products to treat vasomotor symptoms and vulvar and vaginal atrophy symptoms-recommendations for clinical evaluation. January 2003. Available at: Http://www.fda.gov/downloads/Drugs/Guidance ComplianceRegulatoryInformation/Guidances/UCM071643.pdf [Last accessed 14 June 2013
2. Levine KB, Williams RE, Hartmann KE. Vulvovaginal atrophy is strongly associated with female sexual dysfunction among sexually active postmenopausal women. Menopause 2008;15(4 Pt 1):661-6
3. Genazzani AR, Schneider HP, Panay N, et al. The European Menopause Survey 2005: Women's perceptions on the menopause and postmenopausal hormone therapy. Gynecol Endocrinol 2006;22:369-75
4. Nappi RE, Kokot-Kierepa M. Women's voices in the menopause: Results from an international survey on vaginal atrophy. Maturitas 2010;67:233-8
5. Kingsberg SA, Wysocki S, Magnus L, et al. Vulvar and vaginal atrophy in postmenopausal women: Findings from the REVIVE (Real Women's Views of Treatment Options for Menopausal Vaginal ChangEs) Survey. J Sex Med 2013;10:1790-9
6. Lester J, Bernhard L, Ryan-Wenger N. A self-report instrument that describes urogenital atrophy symptoms in breast cancer survivors. West J Nurs Res 2012;34:72-96
7. Macbride MB, Rhodes DJ, Shuster LT. Vulvovaginal atrophy. Mayo Clin Proc 2010;85:87-94
8. Sturdee DW, Panay N. Recommendations for the management of postmenopausal vaginal atrophy. Climacteric 2010;13:509-22
9. Goldstein I. Recognizing and treating urogenital atrophy in postmenopausal women. J Womens Health (Larchmt) 2010;19:425-32
10. Van Voorhis BJ. Genitourinary symptoms in the menopausal transition. Am J Med 2005;118(12B):47-53S
11. Jackson SL, Scholes D, Boyko EJ, et al. Predictors of urinary incontinence in a prospective cohort of postmenopausal women. Obstet Gynecol 2006;108:855-62
12. American College of Obstetricians and Gynecologists. Genitourinary tract changes. Obstet Gynecol 2004;104(4 Suppl):56-61S
13. Frank SM, Ziegler C, Kokot-Kierepa M, et al. Vaginal Health: Insights, Views & Attitudes (VIVA) survey-Canadian cohort. Menopause Int 2013;19:20-7
14. Nappi RE, Kokot-Kierepa M. Vaginal Health: Insights, Views & Attitudes (VIVA)-results from an international survey. Climacteric 2012;15:36-44
15. Simon JA, Kokot-Kierepa M, Goldstein J, et al. Vaginal health in the United States: Results from the Vaginal Health: Insights, Views & Attitudes survey. Menopause 2013;20:1043-8
16. Nappi RE, Davis SR. The use of hormone therapy for the maintenance of urogynecological and sexual health post WHI. Climacteric 2012;15:267-74
17. Foxman B. Epidemiology of urinary tract infections: Incidence, morbidity, and economic costs. Dis Mon 2003;49:53-70
18. Chahal HS, Drake WM. The endocrine system and ageing. J Pathol 2007;211:173-80